wrapping a gold wire around the silicon tube about 50 mm from the electrode tip. Electrode impedances were below 6 kiloohms at 1 kHz. Impedances were regularly checked to ensure proper function. 10. Additional control data were published in (7) 
supragranular layers occurs only shortly delayed in comparison with the activity in granular layers. This most likely reflects direct activation of these layers from layer IV. Long-lasting activation of infragranular layers is seen next, corresponding well with the functional anatomy of normal auditory cortex. There was almost no activation of infragranular layers in naïve deaf cats. The CSD signals were significantly lower than in normal controls (highest mean sink amplitude ϭ 1117 V/mm 2 in comparison with 1385 V/mm 2 ; one-tailed Wilcoxon-Mann-Whitney test, P Ͻ 0.05). After long-term electrical stimulation, in chronic animals, a pattern similar to normal hearing acutely deafened cats was observed. Sink amplitudes were significantly higher than in naïve CDCs (highest mean value ϭ 1805 V/mm 2 ); they were also 30% higher than those of normal controls, but the difference between chronically stimulated deaf and normal cats was nonsignificant. 18 Chemotherapy and radiation therapy for cancer often have severe side effects that limit their efficacy. Because these effects are in part determined by p53-mediated apoptosis, temporary suppression of p53 has been suggested as a therapeutic strategy to prevent damage of normal tissues during treatment of p53-deficient tumors. To test this possibility, a small molecule was isolated for its ability to reversibly block p53-dependent transcriptional activation and apoptosis. This compound, pifithrin-␣, protected mice from the lethal genotoxic stress associated with anticancer treatment without promoting the formation of tumors. Thus, inhibitors of p53 may be useful drugs for reducing the side effects of cancer therapy and other types of stress associated with p53 induction.
p53 functions as a key component of a cellular emergency response mechanism. In response to a variety of stress signals, it induces growth arrest or apoptosis, thereby eliminating damaged and potentially dangerous cells from the organism (1) . The p53 gene is lost or mutated in most human tumors (2) . Lack of functional p53 is accompanied by high rates of genomic instability, rapid tumor progression, resistance to anticancer therapy, and increased angiogenesis (3). p53 deficiency in mice is associated with a high frequency of spontaneous cancers (4) . On the basis of all these observations, the inactivation of p53 is viewed as an unfavorable event, and much effort has been expended to facilitate anticancer treatment by restoring p53 function. However, the role of p53 in cancer treatment is not limited to its involvement in killing tumor cells. In mice, the p53 gene is highly expressed in several normal tissues, including lymphoid and hematopoietic organs, intestinal epithelia, and the testis, and it is these tissues that are damaged by anticancer therapy (5, 6) . p53-dependent apoptosis occurs in sensitive tissues shortly after gamma irradiation (6, 7) , and p53-deficient mice survive higher doses of gamma irradiation than do wild-type animals (8) . These data indicate that p53 is a determinant of the toxic side effects of anticancer treatment, and thus may be an appropriate target for therapeutic suppression to reduce the damage to normal tissues (9) . This approach would be applicable only for tumors that lack functional p53.
To explore the feasibility of this approach, we isolated a chemical inhibitor of p53 and characterized its effects in vitro and in vivo. As a primary read-out system for screening of p53 inhibitors, we used the mouse ConA cell line, which carries the wild-type p53 gene and the bacterial lacZ reporter gene under the control of a p53-responsive promoter (6) . Because the inhibitors of p53 transactivation may not necessarily suppress apoptosis, the selected compounds were then tested in mouse cell line C8, a conventional model of p53-dependent apoptosis (10) . Individual compounds from a diverse collection of 10,000 synthetic chemicals (from DIVERSet, Chembridge Corporation, San Diego, California), in combination with the potent p53 inducer, doxorubicin (Dox), were added to ConA cells growing in 96-well plates, and activation of lacZ-encoded ␤-galactosidase (␤-Gal) was determined by routine X-Gal staining after 24 hours of treatment (Fig. 1A) . We chose compounds that attenuated ␤-Gal induction in Dox-treated cells with no effect on cell growth or survival rate and picked one of them for a detailed characterization. This synthetic, water-soluble, and stable compound, with a molecular weight of 367, blocked activation of p53-responsive lacZ in ConA cells induced not only by Dox but also by ultraviolet (UV) light (Fig. 1 , B and C) and gamma radiation (10) in a dose-dependent manner. This compound also reduced activation of endogenous cellular p53-responsive genes, including cyclin G, p21/ waf1/cip1, and mdm2, as judged by Northern (RNA) blot hybridization (Fig. 1D) . We named it pifithrin-␣ (PFT␣, an abbreviation for "p-fifty three inhibitor") (Fig. 1E) .
To analyze the effect of PFT␣ on p53-mediated apoptosis, we used mouse embryo fibroblasts transformed with E1aϩras, line C8, which undergo rapid p53-dependent apoptosis in response to a variety of treatments (11) . A 10 M concentration of PFT␣ inhibited apoptotic death of C8 cells induced by Dox, etoposide, Taxol, cytosine arabinoside ( Fig. 2A) , UV light, and gamma radiation (10) . The anti-apoptotic activity of PFT␣ was p53-dependent because it had no effect on the survival of UV-treated C8-56 cells, in which p53 is suppressed by a dominant negative mutant, GSE56 (12) (Fig. 2B) , or of E1aϩras-transformed fibroblasts from p53 Ϫ/Ϫ mouse embryos, line A4 (10, 11) . Similarly, PFT␣ inhibited p53-dependent growth arrest of human diploid fibroblasts in response to DNA damage but had no effect on p53-deficient fibroblasts. Suppression of both p53-dependent apoptosis and growth arrest by PFT␣ correlated with an increase in long-term cell survival, as judged by the results of assays of colony growth (13) . To test whether PFT␣ affects p53-dependent cell cycle checkpoint control, we compared the cell cycle distribution of treated ConA cells before and after gamma irradiation (Fig. 2C) . PFT␣ had no effect on nonirradiated cells, but it dramatically increased the proportion of G 2 -arrested cells 24 hours after gamma irradiation. This effect was p53-dependent because it was completely abrogated in the GSE56 cells, which have no functional p53 (Fig. 2C) .
To determine the stage in the p53 pathway that is targeted by PFT␣, we analyzed the compound's effects when apoptosis was induced by direct overexpression of wild-type p53 with no genotoxic stress applied. PFT␣ dramatically inhibited killing of p53-deficient human sarcoma Saos-2 cells that in control cells occurred within 48 hours after transient transfection with p53-expressing plasmids (Fig. 3A) . This suggests that PFT␣ acts downstream of p53. PFT␣ did not alter phosphorylation or sequence-specific DNA binding of p53 in ConA cells after DNAdamaging treatments, as judged by protein immunoblotting in combination with twodimensional protein analysis and gel shift assays (Fig. 3, B through E) . However, it slightly lowered the levels of nuclear, but not cytoplasmic, p53 induced by UV irradiation. In contrast, PFT␣ did not affect the nuclear-cytoplasmic ratio of the p53-inducible p21 waf1 protein (Fig. 3D ). These observations suggest that PFT␣ may modulate the nuclear import or export (or both) of p53 or may decrease the stability of nuclear p53. Whether this is the only mechanism of PFT␣ action remains unclear.
We also characterized the dependence of cell survival after genotoxic stress on the time and duration of PFT␣ application (13) . PFT␣ had almost no protective effect if it was added before (up to 18 hours) and removed immediately before UV treatment of C8 cells. However, a short 3-hour incubation with PFT␣ after UV treatment had a pronounced protective effect, whereas a 24-hour incubation provided maximal protection. PFT␣ did not rescue UV-irradiated cells from apoptosis if it was added 3 hours after UV irradiation. These observations indicate that although PFT␣ can efficiently inhibit p53-dependent apoptosis, its effects are reversible and require the presence of the drug. Because many cells survived a lethal dose of UV irradiation after only 3 hours of incubation with PFT␣, we conclude that the UV-induced apoptotic death signal is significantly reduced within several hours and completely disappears within 24 hours of irradiation.
To analyze the in vivo effects of PFT␣, we treated two different strains of mice (C57BL and Balb/c) with lethal and sublethal doses of whole-body gamma radiation. We compared (i) untreated unirradiated mice, (ii) unirradiated mice that received a single intraperitoneal (i.p.) injection of PFT␣, (iii) untreated gamma-irradiated mice, and (iv) mice injected intraperitoneally with PFT␣ immediately before gamma irradiation. PFT␣ treatment 14 Cthymidine (10 mCi per animal) was injected intraperitoneally into untreated wild-type or p53-null mice and in gamma irradiated mice 8 hours after 10 Gy of wholebody gamma irradiation. A subgroup of the gamma-irradiated animals received one i.p. injection of PFT␣ (2.2 mg/kg) 5 min before irradiation. Mice were killed 24 hours after 14 C-thymidine injection, and whole-body sections (25 m thick) were prepared and exposed with x-ray film in order to monitor the tissue distribution of 14 C. Red arrows indicate skin and intestine. (C) Comparison of tissue morphology and apoptosis ( TUNEL staining) in the epithelium of the small intestine of C57BL6 p53 wild-type mice 24 hours after 10 Gy of whole-body gamma irradiation. Areas of massive apoptosis are indicated by blue arrows.
completely rescued mice of both strains from 60% killing doses of gamma irradiation (8 Gy for C57BL and 6 Gy for Balb/c). Significant protection was also seen at higher doses of irradiation that were lethal for control animals (Fig. 4A) . PFT␣-injected mice lost less weight than irradiated mice that were not pretreated with the drug (Fig. 4B) . PFT␣ did not protect p53-null mice from lethal irradiation, which confirms that it acts through a p53-dependent mechanism in vivo (13) .
Drug-mediated suppression of p53 results in the survival of cells that otherwise would be eliminated by p53 and that may increase the risk of new cancer development. In fact, p53-deficient mice are extremely sensitive to radiation-induced tumorigenesis (14) . However, in our study, no tumors or any other pathological lesions were found in the group of 30 survivors rescued from lethal gamma irradiation by PFT␣, even at 7 months after irradiation. Thus, temporary suppression of p53 appears to differ from p53 deficiency in terms of cancer predisposition.
To monitor PFT␣ activity at the tissue level, we compared the effect of gamma radiation on DNA synthesis in tissues in PFT␣-treated and untreated mice using a 14 C-thymidine incorporation assay. 14 C labeling of skin, gut, and several other tissues was significantly decreased after gamma irradiation in p53 ϩ/ϩ mice but not p53 Ϫ/Ϫ mice, reflecting the p53 dependence of the effect. The radiation-induced decrease in 14 C-thymidine incorporation was less pronounced in PFT␣-treated mice than in control irradiated animals, presumably reflecting PFT␣ inhibition of p53 (Fig. 4B) . These results suggest that PFT␣ attenuates the p53-dependent block of DNA replication in rapidly proliferating tissues after whole-body gamma irradiation. Changes in thymidine incorporation correlated with the extent of apoptosis in the gut epithelium of gamma-irradiated mice. The extensive apoptosis observed in the crypts and villi of the small intestine was abrogated in mice treated with PFT␣ before irradiation (Fig. 4C) .
Our results raise the possibility of using PFT␣ (or other compounds with similar activity) to reduce the side effects of radiation therapy or chemotherapy for human cancers that have lost functional p53. Because the effects of PFT␣ are p53-dependent, the compound should not affect the sensitivity of such tumors to treatment. In fact, i.p. injection of PFT␣ did not change the radiation response of p53-deficient tumor xenografts in p53 ϩ/ϩ nude mice (15) . It is likely that suppression of p53-dependent apoptosis has already been successfully and broadly applied to cancer patients in the form of growth factors supplementing chemotherapy (16) . The therapeutic effect of such supplements may be associated with their activity as survival factors suppressing p53-dependent apoptosis (17) . PFT␣ can now be used to determine whether there are any other clinical situations in which p53 suppression might be desirable. These include heart and brain ischemia, which both result from local hypoxia, a potent activator of p53 (18) . Systematic screening of synthetic and natural compounds may lead to the identification of additional p53 inhibitors that may protect tissue from the consequences of a variety of stresses.
